Literature DB >> 10772604

Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients.

H M Pettinati1, J R Volpicelli, J D Pierce, C P O'Brien.   

Abstract

The effectiveness of naltrexone, a FDA-approved medication for alcohol dependence, can be improved if we support and help patients to consistently take their medication. We illustrate how patient noncompliance with treatment negatively affects outcome, and, we describe a new intervention to enhance medication compliance. Outcome was evaluated for 196 alcohol dependent outpatients who were treated with 50 mg/day naltrexone or placebo for 12 weeks. For patients who adhered to the prescribed treatment, relapse rates were lower with naltrexone than placebo (10% vs. 38.6%, p < 0.001). For noncompliant patients, relapse rates were high and comparable between naltrexone- and placebo-treated patients (42.9% vs. 40%). In a second study of 100 alcohol dependent outpatients, we introduced an intervention that resulted in better medication compliance rates compared to a previous naltrexone study of patients who did not receive the intervention (77.0% vs. 60.8%, p < 0.01). This provided some support for the use of an intervention that targets medication compliance when prescribing naltrexone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772604     DOI: 10.1300/J069v19n01_06

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  39 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

2.  New pharmacotherapies for treating the neurobiology of alcohol and drug addiction.

Authors:  Helen M Pettinati; Amanda R Rabinowitz
Journal:  Psychiatry (Edgmont)       Date:  2006-05

3.  The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.

Authors:  Aron N Starosta; Robert F Leeman; Joseph R Volpicelli
Journal:  J Psychiatr Pract       Date:  2006-03       Impact factor: 1.325

4.  Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy.

Authors:  Jaimee L Heffner; Giao Q Tran; Candace S Johnson; Suzan Winders Barrett; Thomas J Blom; Rachel D Thompson; Robert M Anthenelli
Journal:  J Stud Alcohol Drugs       Date:  2010-01       Impact factor: 2.582

5.  Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study.

Authors:  Jennifer G Plebani; David W Oslin; Kevin G Lynch
Journal:  Am J Addict       Date:  2011-05-31

Review 6.  The opioidergic-alcohol link : implications for treatment.

Authors:  Vania Modesto-Lowe; Eleanor M Fritz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen
Journal:  J Subst Abuse Treat       Date:  2013-03-13

8.  What happens when people discontinue taking medications? Lessons from COMBINE.

Authors:  Robert L Stout; Jordan M Braciszewski; Meenakshi Sabina Subbaraman; Henry R Kranzler; Stephanie S O'Malley; Daniel Falk
Journal:  Addiction       Date:  2014-09-12       Impact factor: 6.526

9.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Authors:  Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

Review 10.  Naltrexone for the management of alcohol dependence.

Authors:  Raymond F Anton
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.